Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14488947 | 1.00 | HPGD (0.42) | HPGDLMNAALDH1A1TSHRALOX12 | |
| SCHEMBL14489289 | 0.85 | HDAC8 (0.41) | HPGDLMNAALDH1A1TSHRALOX12 | |
| SCHEMBL5402517 | 0.85 | LMNA (0.45) | HPGDLMNAALDH1A1TSHRALOX12 | |
| SCHEMBL4128233 | 0.84 | ATM (0.46) | LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4128238 | 0.84 | ATM (0.46) | LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL8996273 | 0.81 | CA12 (0.42) | LMNAHTTKMT2A | |
| SCHEMBL8996263 | 0.81 | CA12 (0.42) | LMNAHTTKMT2A | |
| SCHEMBL2386328 | 0.80 | TSHR (0.46) | HPGDLMNAALDH1A1TSHRALOX12 | |
| SCHEMBL22950649 | 0.80 | TSHR (0.46) | HPGDLMNAALDH1A1TSHRALOX12 | |
| SCHEMBL30797243 | 0.80 | TSHR (0.46) | HPGDLMNAALDH1A1TSHRALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7232923-B2 | Method of hydroaminating N-alkenoylcarbamates with primary aromatic amines | IMPERIAL INNOVATIONS LIMITED (GB) | 2007-06-19 | — | — | US | disclosed |
| US-20060183933-A1 | Method of hydroaminating N-alkenoylcarbamates with primary aromatic amines | IMPERIAL COLLEGE INNOVATION LIMITED (GB) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183933-A1 | Method of hydroaminating N-alkenoylcarbamates with primary aromatic amines | ALKBH3, HNMT, ALKBH1 | HPGD 1275/4885LMNA 631/4885ALDH1A1 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.